Skip to content
Government NT, Medical Health Aged Care

Bill Shorten MP to visit NT’s Project21 Tomorrow

Down Syndrome Assocation of NT 2 mins read
Down Syndrome NT will welcome Honorable guests including Bill Shorten MP Minister for the NDIS to the Project21 learning centre in Coconut Grove tomorrow (March 13).
 
An initiative of the Down Syndrome Association of the Northern Territory, Project21 offers school leavers with Down Syndrome and other learning difficulties additional support in their journey from adolescence to adulthood.

Over the last decade of operation, a full curriculum has been developed and is delivered by qualified teachers and support staff, offering certificate level education, work skills training, social skills and independent life skills development.

Today, Project21 supports 26 young people through attendance in class, activities in the community and active employment.

Project21 is offered at a time when people living with Down Syndrome can expect greater community inclusion, opening doors to better employment opportunities, development of meaningful relationships and even independent living.

With the life expectancy for people with Down Syndrome now surpassing 60 years of age (compared to just 25 years old in the 1980’s), it is imperative that programs like Project21 continue to operate and receive the necessary funding to ensure adolescents and young adults are provided with the tools they will need to serve them throughout life.

Media are invited to attend the event tomorrow to gain interviews and vision of Minister meeting with students and staff of Project 21.

Ministerial Visit to Project21 Event Details

When: Wednesday 13 March / 10.15am to 11.15am (sharp)

Where: DSANT Project21 HQ: Unit 6, 1 Caryota Court, Coconut Grove

In attendance:

The Honourable Bill Shorten MP Minister for the NDIS
The Honourable Vicki O’Halloran AO CVORepresentatives of the Down Syndrome Community (current students of Project21)Senior management of Down Syndrome NT

About Down Syndrome Association of the Northern Territory

DSANT was formed in 1979 by parents of babies with Down syndrome living in Darwin. Forty-five years later the Association remains committed to providing support and services to families across the Northern Territory which includes visiting urban, rural and remote communities, schools and hospitals, gathering people together in peer support groups and raising community awareness about Down syndrome.

Families and individuals who would like more information about Project21 are encouraged to contact the Executive Officer, Down Syndrome Association NT for further information pertaining to programs and enrolment criteria.


Contact details:

Media interested in attending tomorrow’s event can contact Rachel Kroes (CEO Down Syndrome NT) 0455 256 606 / [email protected]

Media

More from this category

  • Medical Health Aged Care
  • 11/02/2026
  • 06:31
Breast Cancer Network Australia

She Reached Everest before Taking on Breast Cancer — Now Port Macquarie local tackling Kilimanjaro for First Nations Communities

ProudJawoyn and Wiradjuri woman and Port Macquarie local, Kristal Kinsela, is preparing to climb Mount Kilimanjaro to raise critical support for First Nations people…

  • Contains:
  • Food Beverages, Medical Health Aged Care
  • 11/02/2026
  • 05:30
VicHealth, Australian Medical Association, The George Institute for Global Health

Health leaders push for mandatory Health Star Ratings to protect Australians’ health

Leading health organisations have written to Australia’s food ministers, urging them to make Health Star Ratings mandatory on all packaged foods. They say the…

  • Contains:
  • Medical Health Aged Care
  • 10/02/2026
  • 23:41
Helus Pharma

Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution

Former President of Shire PLC’s (“Shire”) Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior leadership roles at Astra-Merck and AstraZeneca PLCProven leader in late-stage clinical development, global commercialization, and capital formation across central nervous system (“CNS”) programsAppointed as Helus Pharma advances its pipeline toward key clinical milestones, including expected Phase 2 data for HLP004 this quarter and Phase 3 topline data for HLP003 later this yearThis news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.